- Home
- SNDX vs ADEA Comparison
SNDX vs ADEA Comparison
Compare SNDX & ADEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNDX | ADEA |
|---|---|---|
| Founded | 2005 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNDX | ADEA |
|---|---|---|
| Price | $20.93 | $12.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $36.92 | $19.50 |
| AVG Volume (30 Days) | ★ 2.1M | 728.2K |
| Earning Date | 11-03-2025 | 11-03-2025 |
| Dividend Yield | N/A | ★ 1.53% |
| EPS Growth | N/A | ★ 75.65 |
| EPS | N/A | ★ 0.65 |
| Revenue | $111,304,000.00 | ★ $379,912,000.00 |
| Revenue This Year | $620.14 | N/A |
| Revenue Next Year | $115.42 | $10.13 |
| P/E Ratio | ★ N/A | $20.16 |
| Revenue Growth | ★ 595.65 | 10.53 |
| 52 Week Low | $8.58 | $10.59 |
| 52 Week High | $21.22 | $18.25 |
Technical Indicators
Market Signals| Indicator | SNDX | ADEA |
|---|---|---|
| Relative Strength Index (RSI) | 67.42 | 45.00 |
| Support Level | $20.00 | $12.32 |
| Resistance Level | $21.22 | $13.68 |
| Average True Range (ATR) | 0.93 | 0.38 |
| MACD | 0.02 | 0.22 |
| Stochastic Oscillator | 85.90 | 50.32 |
Price Performance
Historical ComparisonAbout SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.